Pre-treatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity

Int J Cancer. 1992 Feb 20;50(4):644-8. doi: 10.1002/ijc.2910500427.

Abstract

The effect of L-asparaginase (L-asp) pre-treatment on etoposide-induced DNA strand breakage and cytotoxicity was investigated. In a T-lymphoblastoid cell line, Molt 4, etoposide-induced DNA strand breaks, DNA-protein cross-links and cytotoxicity were reduced by pre-treatment with L-asp for 15 hr, but it did not cause these changes in a promyelocytic-leukemia cell line, HL-60, which is less sensitive than Molt 4 to L-asp. However, pre-treatment of Molt 4 cells with L-asp did not significantly alter the accumulation of [3H]-etoposide. Cell-cycle analyses showed an increase in G1-phase cells, a significant decrease in both S-phase cells and G2/M-phase cells pre-treated with L-asp in Molt 4 cells, but L-asp exposure did not result in any significant changes in HL-60 cells. On the other hand, L-asp pre-treatment did not affect topoisomerase-I (Topo-I) inhibitor, camptothecin (CPT)-induced DNA strand breaks or toxicity in Molt 4 cells. Our data imply that a decrease in S- and G2/M-phase cells following L-asp treatment may explain the reduction of etoposide-induced DNA lesions and cytotoxicity in Molt 4 cells, since topoisomerase-II (Topo-II) content or activity is a function of cellular proliferation status.

MeSH terms

  • Asparaginase / pharmacology*
  • Camptothecin / pharmacology
  • Cell Cycle / drug effects
  • Cross-Linking Reagents
  • DNA / drug effects*
  • DNA Damage*
  • Etoposide / antagonists & inhibitors*
  • Etoposide / metabolism
  • Etoposide / toxicity
  • Humans
  • In Vitro Techniques
  • Tumor Cells, Cultured

Substances

  • Cross-Linking Reagents
  • Etoposide
  • DNA
  • Asparaginase
  • Camptothecin